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A	 case	 of	 human	melioidosis	 caused	 by	 a	 novel	 se-
quence type of Burkholderia pseudomallei occurred in a 
child in Malawi, southern Africa. A literature review showed 
that	human	cases	 reported	 from	 the	continent	have	been	
increasing.
Melioidosis is widely distributed in tropical and sub-tropical regions, but data are lacking on this disease 
in sub-Saharan Africa. We report a case of melioidosis 
caused by a novel sequence type in a 16-month-old boy 
from rural Malawi. Increasing reports of melioidosis from 
Africa indicate a need for further investigation.
Case Report
A 16-month-old boy was seen at Queen Elizabeth Cen-
tral Hospital (QECH), Blantyre, Malawi, in March 2011 
with fever of 18 days’ duration, poor feeding, subcutaneous 
lesions of 15 days’ duration, and edema of the hands and 
feet. He had received intravenous (IV) benzylpenicillin and 
gentamicin for 4 days at a local health center before being 
referred for persistent fever.
The family lived in a remote village in the Shire Val-
ley near the Malawi–Mozambique border at a latitude of 
–15°S; daytime temperature average was 27°–29°C, and 
natural flooding occurs from October through April. The 
boy’s parents were subsistence maize farmers and kept 
goats and pigs.
On arrival at QECH, the child was irritable and pale; 
temperature was 38.7°C, weight 9.8 kg (weight-for-age 
z score –1.14), and height 79 cm (weight-for-height z 
score –1.06). He had bilateral dactylitis with arthritis of 
the metacarpophalangeal and interphalangeal joints of the 
lateral 3 fingers. Numerous rubbery, tender subcutaneous 
nodules of ≈2 cm diameter were palpable on the face, tho-
rax, and limbs. Overlying hyperpigmentation and weepy 
ulcerations occurred over some nodules. There was cervi-
cal and inguinal lymphadenopathy but no hepatospleno-
megaly. Symmetric bipedal pitting edema extended to the 
knees. Neurologic, cardiovascular, and respiratory exami-
nations revealed no abnormalities.
Laboratory results were as follows: blood glucose 7.8 
mmol/L (reference 3.5–7.7 mmol/L), hemoglobin 4.6 g/dL 
(reference 9.7–15.1 g/dL), leukocyte count 31.9 × 103/µL 
(reference 3.9–10.7 × 103/µL), and erythrocyte sedimen-
tation rate 95 mm/h (reference 3–13 mm/h). Blood smear 
showed poikilocytes with some tear drops and reticulocytes 
and was negative for malaria parasites. HIV test (Unigold; 
Trinity Biotech, Bray, Ireland) and VDRL (Venereal Dis-
ease Research Laboratory) test for syphilis were negative. 
Radiographs of the hand showed bilateral osteolytic reac-
tions in the lateral 3 fingers. Chest radiograph and abdomi-
nal ultrasound indicated no abnormalities.
Culture (BacT/Alert PF; bioMérieux, Marcy l’Etoile, 
France) of blood taken on admission and aspirate of pus 
from a subcutaneous nodule grew white, oxidase-positive 
colonies of gram-negative rods, and the biochemical profile 
(API 20NE; bioMérieux) strongly suggested Burkholderia 
pseudomallei (1556575: B. pseudomallei [98.3% identi-
ty]). The API profile from the pus isolate (1156154) initial-
ly suggested Chromobacterium violaceum, a recognized 
misidentification of B. pseudomallei, by API profiling (1). 
Antimicrobial susceptibility by disk diffusion indicated re-
sistance to gentamicin and susceptibility to co-amoxiclav; 
colistin disk testing was unavailable. Because B. pseudom-
allei has not been reported from Malawi, we sought to con-
firm the isolate by real-time PCR, targeting the highly spe-
cific type III secretion system (2). DNA was extracted by 
using a Wizard Genomic Purification kit (Promega, Madi-
son, WI, USA), and real-time PCR was performed on an 
Applied Biosystems 7900HT (Applied Biosystems, Foster 
City, CA, USA) by using a technique modified for SYBR 
green detection (2). This PCR confirmed the identity of the 
organism as B. pseudomallei. Whole-genome sequencing 
(WGS) was performed by using the MiSeq Personal Se-
quencer (Illumina, San Diego, CA, USA), which enabled 
multilocus sequence typing (MLST) (3) and revealed a 
novel allelic combination (1,3,3,1,5,1,1). This sequence 
type (ST) has been submitted to the MLST database (http://
bpseudomallei.mlst.net/) and has been assigned MLST 
ST1008, part of clonal complex 1.
The boy was given chloramphenicol for empiric treat-
ment of systemic bacterial infection before the isolate was 
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identified. In light of the anthropometric values, anorex-
ia, fecal morphology, and symmetric pedal edema, acute 
kwashiorkor was diagnosed, and nutritional rehabilitation 
was begun. Pedal edema and anorexia improved after 48 
hours. At 96 hours, B. pseudomallei infection was diag-
nosed, and treatment was changed to IV ceftazidime. Fever 
abated by day 7, and after 30 days of IV ceftazidime, the 
nodules had involuted and the dactylitis and arthritis had 
resolved. At the family’s request, the child was discharged 
on a 6-month regimen of cotrimoxazole, rather than the 
planned 6-week IV regimen for osteomyelitis.
Four weeks after discharge, the child remained well 
with no fevers and no new lesions; clinical anemia had re-
solved, and repeat radiographs showed that the hands were 
within normal limits. He was then lost to follow-up.
Conclusions
Melioidosis is acquired through the skin or possibly by 
inhalating the environmental organism B. pseudomallei. It 
causes a wide spectrum of clinical disease–from localized 
skin infection to severe acute septicemia–but progresses to 
disease in only a small proportion of exposed persons (4). 
B. pseudomallei is endemic in Southeast Asia and Northern 
Australia and typically is distributed from latitude 20°N to 
latitude 20°S, particularly in association with wet soil (4).
Sporadic cases have been documented in all inhab-
ited continents, but a lack of diagnostic microbiological 
facilities and systematic studies in many low-income re-
gions limit knowledge of the true distribution of the dis-
ease (5), a particular problem in rural sub-Saharan Africa. 
Although the relationship between human and animal 
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Table	1.	Melioidosis	in	animals,	Africa 
Year	
(reference) Country Animal Clinical characteristics Method of identification 
1936	(6) Madagascar Pig Lymphadenopathy Passaged through guinea pig (tissue from 
submaxillary	gland) 
1960 (7) Chad Goat Lymphadenopathy Isolated from mesenteric ganglia 
1960 (8) Africa* Camel Retropharyngeal	abscess Inoculation and sacrifice of guinea pig 
1972 (8) Niger,	Burkina	
Faso  
Pigs (>100 cases) Abscesses	in	liver,	spleen,	and	lung	
in apparently healthy pigs 
Not	described 
1995	(9) South Africa Goat Mammary gland and renal	abscesses Biochemical and phenotypic 
characteristics 
*Specific country of acquisition was not detailed. 
 
Table	2.	Melioidosis	in	humans,	Africa* 
Year	
(reference) 
 
Country where 
acquired 
(diagnosed) 
Details of 
infected 
persons Clinical characteristics 
Diagnostic method 
(source of isolation) 
Definitive 
treatment 
(duration, wk) Outcome 
1982 (10) Kenya	(Denmark) Adult Sepsis Culture	(blood,	urine,	
sputum) 
OTC (4); 
cotrimoxazole	
TMP-SXT (8) 
Complete 
recovery 
1985	(11) Sierra	Leone	
(Gambia) 
Child Cutaneous 
abscesses,	
osteomyelitis 
Culture; indirect 
hemagglutination (pus) 
CHL,	TET Improved; 
lost to 
follow-up 
2004 (12) Mauritius 
(Mauritius) 
Adult	with	SLE Sepsis, cellulitis Culture;	API	2ONE	
(blood) 
None Died (d 9) 
2004 (13) Madagascar  
(La	Réunion) 
Adult smoker, 
alcoholic 
Sepsis, respiratory 
distress 
Culture	(blood,	BAL	
fluid) 
CAZ Complete 
recovery 
  Adult with CPI Septicemia Culture	(blood,	BAL	
fluid) 
CAZ; 
cotrimoxazole	(20) 
Not	
described	 
  Adult	with	SLE Septicemia Culture	(blood,	BAL	
fluid) 
CAZ; 
cotrimoxazole	(20) 
Not	
described 
2006 (14) Madagascar  
(La	Réunion) 
Adult smoker Pneumonia Culture; API 20NE;	
PCR	(BAL	fluid); 
IPM (2); 
cotrimoxazole	(20) 
Resolution 
at	3	mo 
2010 (15) Africa† (France) Adult Mycotic aneurysm Culture	(blood,	arterial	
tissue) 
IPM	+	CIP	(5);	
cotrimoxazole	(20) 
Resolution 
at 6 mo 
2011 (16) Gambia	(Spain) Adult with 
diabetes	
mellitus 
Pyomyositis, 
pneumonia 
Culture; PCR (pus, 
sputum) 
CAZ + 
cotrimoxazole	(5);	
DOX + 
cotrimoxazole	(20) 
Complete 
recovery 
2011 (17) Nigeria	(UK) Adult with 
diabetes	
mellitus 
Localized	
lymphadenopathy 
Culture; 
chromatography; PCR 
(blood) 
Meropenem (1); 
cotrimoxazole	(12) 
Lost	to	
follow-up 
2011 (18) Africa† (Spain) Adult Sepsis Culture	(blood) CAZ + DOX Not	
described 
*OTC,	oxytetracycline;	TMP-SXT, trimethoprim–sulfamethoxazole;	CHL,	chloramphenicol;	TET,	tetracycline;	SLE,	systemic	lupus	erythematosus;	BAL,	
bronchoalveolar	lavage;	CAZ,	ceftazidime;	CPI,	chronic	pulmonary	insufficiency;	IPM,	imipenem;	CIP,	ciprofloxacin;	DOX,	doxycycline; MER, 
meropenem. 
†Exposure	was	in	multiple	countries	on	the	continent	or	the	specific	country	of	acquisition was not detailed. 
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infection is not precisely understood, infections of ani-
mals have been recognized throughout the continent 
(Table 1) (6–9). During the past 30 years, 11 cases of hu-
man melioidosis acquired in Africa (1 in a child) have 
been reported in the literature (Table 2 [10–15; 16–18 
in online Technical Appendix, wwwnc.cdc.gov/EID/
article/19/6/12-0717-Techapp1.pdf]). Three of these cas-
es were PCR confirmed. In many earlier reports, identifi-
cation was not confirmed by methods that would satisfy 
modern taxonomists; thus, the true distribution of melioi-
dosis in Africa remains uncertain.
We used eBURST software (19 in online Technical 
Appendix) to model the relationship between ST1008 
and the global MLST database (online Technical Appen-
dix Figure 1). The founder of this branch of clonal com-
plex 1 is ST916 (online Technical Appendix Figure 2), 
which was isolated from Cambodia. The other STs on this 
branch, ST186 and ST250, were isolated in Thailand. Al-
though none of the other Africa B. pseudomallei isolates 
of known MLST are predicted to be in the same subgroup, 
2 isolates from human infections that are thought to have 
occurred in Kenya (ST5 and ST9; online Technical Ap-
pendix Figure 2) are in the adjacent subgroup. Thus, these 
Malawi and Kenya strains might share a recent common 
ancestor. We have submitted WGS data from our sample 
to a project that is undertaking WGS on a large number 
of B. pseudomallei isolates from around the world. This 
approach is anticipated to offer superior resolution of the 
global phylogeny.
Unfamiliarity with the culture characteristics of B. 
pseudomallei often has resulted in delays in recognition, 
identification, diagnosis, and treatment (1). The organ-
ism exhibits considerable interstrain and media-dependent 
variability in colonial morphology (1); its wrinkled appear-
ance in older colonies may result in their dismissal as con-
taminants. Even relatively expensive biochemical test kits, 
such as the API20NE, may result in misidentification, as 
with the pus isolate here, which raises the question about 
whether the infrequency of the diagnosis is due to rarity of 
the disease or lack of capacity to identify it. B. pseudomal-
lei might be more widespread than recognized in Malawi 
and ecologically similar areas of sub-Saharan Africa where 
the environment is conducive to its growth. Health care 
in Malawi, as in most of sub-Saharan Africa, is delivered 
frequently without use of even basic diagnostic facilities, 
which leads to overdiagnosis of malaria and tuberculosis 
(20 in online Technical Appendix). In this environment, 
patients with septicemic melioidosis could have died be-
fore all locally available empiric treatments had been tried. 
B. pseudomallei is resistant to penicillin, gentamicin, and 
many other antimicrobial drugs used to treat sepsis in the 
tropics, so diagnosis is necessary for appropriate antimi-
crobial therapy.
Melioidosis therefore could be underestimated in 
Malawi and throughout the region. Environmental micro-
biology and seroprevalence studies are required to gauge 
the extent of this infection and to guide local and regional 
health care policy.
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Technical Appendix Figure 1. eBURST diagram of clonal complex 1 Burkholderia pseudomallei sequence types (STs) submitted to the global 
multilocus sequence typing (MLST) database. Diagram shows predicted evolutionary relationship between strains by ST in 7 different alleles. 
Each circle indicates a particular ST, with the relative size of the circle indicating the number of isolations of that particular ST. Blue circle 
indicates the predicted founding genotype (ST48); yellow circles indicate predicted subgroup founders; and purple circle indicates ST1008 from 
the Malawi case described in this report. Lines between STs indicate STs that differ at a single allele. The red square is magnified in Technical 
Page 3 of 3 
Appendix Figure 2 to illustrate more clearly STs closely related to ST1008. The complete database and the eBURST software can be accessed at 
http://bpseudomallei.mlst.net/ 
 
Technical Appendix Figure 2. Detail of eBURST clonal complex 1 subgroup for ST1008. ST1008 is labeled in magenta. The subgroup founder 
ST916 (bottom right) was isolated from samples in Cambodia. In the adjacent subgroup are STs (ST5 and ST-9) isolated from infections in 
humans in Kenya. 
